Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
University researchers highlight noninvasive "histotripsy" therapy and commercialization plans
Summary
Dr. Jen Hsu described histotripsy, a noninvasive ultrasound treatment developed at the University of Michigan, outlined claimed clinical benefits and commercialization milestones including an October 2023 FDA approval for liver tumors and plans for more trials and indications.
Dr. Jen Hsu, a University of Michigan biomedical engineer and radiology professor, told the Board of Regents that histotripsy — a noninvasive, mechanically based ultrasound therapy — liquefies targeted tumor tissue without incision and can be delivered under real-time image guidance.
Hsu said the technique, developed at the university, offers high precision and rapid recovery, and she framed it as a platform for treating tumors in the liver, kidney, pancreas, prostate, brain and shallow targets such as skin and breast lesions. "This is the first noninvasive technology to perform the real surgery, meaning mechanically removed…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
